Is the 2250 MT capacity active, the last credit report on May 2023, says the total pigment capacity is 7500 MT (6000+1500 in the subsidiary).
Posts tagged Value Pickr
Annapurna Swadisht Ltd – A Swadisht FMCG investment? (23-07-2024)
The company previously said that they are going to double the revenue in FY25 and the revenue in FY24 was 265cr & if we break that into a quarter then it is approx 67 cr per qtr of FY24 and if we double it for FY25 Q1. It comes at 134cr per qtr …but the revenue is 90cr only.so it seems like a dip according to the promise made by the company… they are short of approx 32%-33% in revenue of Q1… i hope they will try to boost in upcoming qtrs but the company should disclose the reason to the exchange for the dip … i dont know why they dont disclose anything on regular basis
Annapurna Swadisht Ltd – A Swadisht FMCG investment? (23-07-2024)
The company previously said that they are going to double the revenue in FY25 and the revenue in FY24 was 265cr & if we break that into a quarter then it is approx 67 cr per qtr of FY24 and if we double it for FY25 Q1. It comes at 134cr per qtr …but the revenue is 90cr only.so it seems like a dip according to the promise made by the company… they are short of approx 32%-33% in revenue of Q1… i hope they will try to boost in upcoming qtrs but the company should disclose the reason to the exchange for the dip … i dont know why they dont disclose anything on regular basis
ASM Technologies – Engineering innovation (23-07-2024)
Hi @ankit_george @shanid any idea about the AGM. Any video link? Or do u have any summary of the AGM. If so please share it.
Thanks in advance.
Pondy Oxide & Chemicals (23-07-2024)
Great results & great future prospects.
TARGET 2030 – POCL has laid a clear target which includes capacity expansion of existing verticals (Lead) and diversification into new verticals
(Lithium-ion); having Volume Growth 15%+;
Revenue CAGR and Profitability Growth of 20%+; EBITDA Margins 8%+;
ROCE 20%+;
Value-added Products 60%+;
20%+ Reduction in Energy Consumption to reduce Carbon Footprints.
POCL 1Q25.pdf (633.1 KB)
Ultramarine & Pigments (23-07-2024)
List of the capexes
- FY18: Doing 70 cr. capex for a new surfactant plant in Naidupet (30’000 MTPA capacity; delayed and commercialized in FY21)
- FY21: Greenfield capex of 67 cr. (revised cost: 76 cr.) for premium grade pigments at Naidupet (1’500 MTPA capacity; commercialized in FY22)
- FY22:
- Capex of 21 cr. for specialty chemicals i.e. ingredients for food, cosmetics, personal care (capacity: 1’800 MT) (commercialized in FY23)
- Capex of 24.4 cr. for mixed metal oxides in Naidupet (expected commercialization in FY23)
- Capex for 61.5 cr. for additional pigment capacity in Naidupet (1’500 MTPA)
- FY23
- Capex of 80 cr. in another new Pigments Projects at Naidupeta (capacity: 2250 MT). Expect some portion of the capacity to come online in FY24
- Another project for complex inorganic pigments. Partially completed, balance in FY24. Total cost: 37 cr.
- FY24
- Capex of 80 cr. in pigments (capacity: 1,500 MT) at Naidupeta. Expect commercialization over 18 months, with part of capacity to be commissioned in FY25
AR24 notes
Business related
-
Exports dropped by (-21%) (131 cr. vs 165 cr. in FY23)
-
Export volumes dropped by (-21%). Domestic demand compensated for drop in exports
-
Witnessed pricing pressure across segments due to declining input costs resulting in lower realization. Margins were lower due to high-cost inventory
-
Capacity utilization of Sulphonation plant at Naidupeta improved from H2FY24 and is expected to stabilize in FY25
-
Power & fuel costs : 31.88 cr. (vs 36.17 cr. in FY23)
-
Revenue breakup
-
Other expenses: 68.8 cr. (vs 72.13 cr. in FY23)
Pigment Division:
- Revenue 135 cr. (vs 158 cr. in FY23), -14% and volumes -2%
- Domestic industrial market witnessed robust growth while exports fell
- Expanding customer base in international markets by tapping new areas
- Ultramarine Specialty Chemicals Ltd. achieved a capacity utilization of 82% (revenue of 38 cr. vs 16 cr. in FY23)
Surfactants Division:
- Revenue 343 cr. (vs 333 cr. in FY23)
- Lower realizations. They added more specialty chemicals through in-house development efforts, which will help improve the bottom line
Wind Power Generation
- Own and operate 6 wind turbine generators at 3 locations in Tamil Nadu, capacity of 4.3 MW
- All the units generated are consumed at Ranipet and Ambattur Plants
- Generated 61 lakh units (vs 61.84 lakh units in FY23)
- Captive consumption 61 lakh units (vs 49.36 lakh units in FY23). Green energy contributed 55% of consumption in chemical division
ITeS Division:
- Revenue: 46 cr. (vs 50 cr. in FY23). PAT: 12 cr. (vs 15 cr. in FY23) (exports of 42.08 cr.)
- Scheduled end of certain projects in healthcare caused an overall dip in revenue
Capex
- Subsidiary commissioned a facility to manufacture Inorganic Pigments
- Adding capacity of 1,500 MT in Pigments in the subsidiary at Naidupeta with a capex of 80 cr . Expect commercialization over 18 months, with part of capacity to be commissioned in FY25
- PPE addition is in freehold land (Industrial Park, Naidupet) + buildings and plant & machinery
Subsidiaries
- Ultramarine Fine Chemicals Limited is yet to commence operations
R&D
- One product was commercialized
- Capital: 2.99 cr. (vs 0.3 cr. in FY23). Recurring: 2.17 cr. (vs 1.99 cr. in FY23)
- Total : 5.16 cr. (vs 2.3 cr. in FY23)
Miscellaneous
- Permanent employees : 472 (median remuneration increased by 9%)
- Auditor remuneration : 27.65 lakhs (vs 28.8 lakhs in FY23)
- Shareholders : 22’168 (vs 23’036 in FY23)
- Share price : 306.3 (low), 463.3 (high)
- Investment in Thirumalai : 478.47 cr. (vs 351.36 cr. in FY23) affected by MTM
- Receivables : doubtful of 3.11 cr. (same as FY23). Fully provisioned
- Most bank loans are at 6-9.25%
Disclosure: Invested (no transactions in last-30 days)
Solara Active Pharma Sciences – Pure Play API (23-07-2024)
Solara Active Q1FY25 Concall Summary
Business Updates
- The Vizag facility has been mothballed and being converted to a new facility for the CRAMS business
- The company will be incurring costs for this which will be there only till Q2 and not be present in H2
- The guidance for revenues for FY25 stands at around Rs 1400 crores
- The business has been re worked to its earlier model of major revenues coming from regulated markets and long term contracts that were in place earlier
- The company has reduced debt by around Rs 160 crores including money from rights issue and also free cash that the business has generated
Participants
Systematix
Motilal Oswal
Macquarie
KSA Securities
DAM Capital
QnA
- Currently the Vizag facility is a multipurpose plant but it will be retrofitted to become a CRAMS facility and a High potent API facility
- As of H2 the gross margins will get back at the 48% level
- The Bio Security Act in US is relevant only for biological space and not the API & CDMO space
- By mothballing the Vizag facility the demand supply situation has normalized and there is no excess inventory on ibuprofen now with the Pondicherry facility supplying now
- The capacity for ibuprofen at Vizag is 3000 tons, which in future can be expanded to 9000 tons. This facility will be kept for the future
- The past issues have been taken care of from the rights issue. The free cash generation will be higher than earlier stated guidance
- The key is how many of the RFP’s for CRAMS will get converted
- FY25 will be a year for stabilization with revenues at Rs 1400 crores and debt to EBITDA getting lower
Ultramarine & Pigments (23-07-2024)
Can anyone tell me what is the current capacity in the subsidiary?
Initial 1500 MT was commissioned in FY22. The FY23 Annual report says an additional 2250MT capacity will be added at a cost of 80crs. FY24 annual report says an additional capacity of 1500MT will be added at a cost of 80crs. Have they revised the project downwards or is another new capacity being added?
Oberoi Realty-A simple real estate story (23-07-2024)
Oberoi Realty Q1FY25 Concall Summary
Business Updates
- Another quarter of strong performance despite no new launches
Participants
Ambit Capital
Morgan Stanley
Motilal Oswal
CLSA
Prospero Tree
QnA
- The sales saliency in the Thane project will only get better as customers have appreciated the Kolshet Road project and similar demand should be seen for the Pokhran Road project
- Expecting better sales in the 360 West project since partner has exhausted all inventory and the new projects are 2-3 years into delivery
- In the Glaxo Worli project doing a mixed-use development with a small boutique hotel, a mall and an office project. The developable area should be between 1.6-1.8 million sq foot carpet area
- Currently thinking of 6-8 lakh sq foot of mall, 1 lakh sq foot of hotel and 1 million sq foot of office space in this mixed use project in Worli
- Since company is not allowed to borrow to buy land cash is conserved to take use of an opportunity when it becomes available
- As far as leasing goes will be done 80-90% by this year itself
- As of June 2024 70% area in Commerz III is leased out
- In terms of launches one tower in Goregaon, one tower in Borivali and two towers in Pokhran Road during the festive season will be launched